MultiCell Technologies Inc (MCET)

[jazzbeerman]

katie,
all good questions.
Yes it's a big issue for all BP, and IMO BMY is leading the way. Have a look at the past several issues of Drug Discovery and Development, or look into Stanley Hefta's group in Princeton doing cutting edge work on predicting idiosyncratic hepatotoxicity. I wasn't surprised to see tham as the fist BP client.
There is nothign I can find at the USPTO about this, and I assume they were filed around the same time. Don't know. I DO know and understand very well the advantages of the Multicell line compared to the Crucell line. Grya area is timeline, ROI :)

Re: Newmin gettign the word out. According to the company, it is just beginning. I'm expecting them to show up at UBS in New York this fall, we'll see. As for specific pharma in vitro DDI ADME tox tech conferences, there are a half dozen in the nexr few weeks for the little cell line. I think the company timed the RS as bestthey could, and so far so good- pps is up about 60% from it's post reverse split announcement low, and up about 20% since the split last week...
fingers crossed for continued momentum,
j